Pathology, genetics and cytogenetics of Wilms' tumour

Pathology

Volumn 43, Issue 4, 2011, Pages 302-312

  Md Zin, Reena ^a   Murch, Ashleigh ^a   Charles, Adrian ^a  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

Cytogenetics; Genetics; Pathology; Wilms' tumour

Indexed keywords

EID: 80052227169     PISSN: 00313025     EISSN: 14653931     Source Type: Journal    
DOI: 10.1097/PAT.0b013e3283463575     Document Type: Review

References (150)

1. US Cancer Statistics Working Group. United States Cancer Statistics: 1999-2006 Incidence and Mortality Web-based Report. Atlanta: Department of Health and Human Services, Centers for Disease Control and Prevention and National Cancer Institute, 2010. http://apps.nccd.cdc.gov/ uscs/ childhoodcancerbyprimarysite.aspx
2. Beckwith JB, Kiviat NB, Bonadio JF. Nephrogenic rests, nephroblastomatosis and the pathogenesis of Wilms' tumor. Pediatr Pathol 1990; 10: 1-36. (Pubitemid 20130951)
3. Dome JS, Huff V. Wilms tumor overview. In: Pagon RA, Bird TD, Dolan CR, Stephens K, editors. GeneReviews. Seattle: University ofWashington,2003; Dec 19 (updated 2006 Apr 10). http://www.ncbi.nlm.nih.gov/books/NBK1294/
4. Hentrich MU, Meister P, Brack NG, Lutz LL, Hartenstein RC. Adult Wilms' tumor. Report of two cases and review of the literature. Cancer 1995; 75: 545-51.
5. Kartsanis G, Douros K, Ravazoula P, Fokaefs E. Adult Wilms' tumor: a case report and review of literature. Int Urol Nephrol 2007; 39: 3-6. (Pubitemid 46722926)
6. McDonald JM, Douglass EC, Fisher R, et al. Linkage of familial Wilms' tumor predisposition to chromosome 19 and a two-locus model for the etiology of familial tumors. Cancer Res 1998; 58: 1387-90. (Pubitemid 28193596)
7. Rahman N, Arbour L, Tonin P, et al. Evidence for a familial Wilms' tumour gene (FWT1) on chromosome 17q12-q21. Nat Genet 1996; 13: 461-3. (Pubitemid 26256621)
8. Ruteshouser EC, Huff V. FamilialWilms tumor. Am J Med Genet C Semin Med Genet 2004; 129C: 29-34.
9. Ko EY, Ritchey ML. Current management of Wilms' tumor in children. J Pediatr Urol 2009; 5: 56-65.
10. Breslow N, Beckwith JB, Ciol M, Sharples K. Age distribution of Wilms' tumor: report from the National Wilms' Tumor Study. Cancer Res 1988; 48: 1653-7. (Pubitemid 18091222)
11. Eble JN, Sauter G, Epstein JI, Sesterhenn IA, editors. Tumours of the Urinary System and Male Genital Organs. Lyon: IARC, 2004.
12. Vujanic GM, Sandstedt B, Harms D, Kelsey A, Leuschner I, de Kraker J. Revised International Society of Paediatric Oncology (SIOP) working classification of renal tumors of childhood. Med Pediatr Oncol 2002; 38: 79-82. (Pubitemid 34113435)
13. Faria P, Beckwith JB, Mishra K, et al. Focal versus diffuse anaplasia in Wilms tumor: new definitions with prognostic significance. Am J Surg Pathol 1996; 20: 909-20.
14. Perlman EJ. Pediatric renal tumors: practical updates for the pathologist. Pediatr Dev Pathol 2005; 320: 320-38. (Pubitemid 41204479)
15. Beckwith JB, Palmer NF. Histopathology and prognosis of Wilms tumor. Results from the First National Wilms' Tumor Study. Cancer Met Rev 1978; 41: 1937-48. (Pubitemid 8335406)
16. Zuppan CW, Beckwith JB, Luckey DW. Anaplasia in unilateral Wilms tumor: a report from the National Wilms' Tumor study Pathology Centre. Hum Pathol 1988; 19: 1199-209.
17. Beckwith JB. Precursor lesions of Wilms tumor: Clinical and biological implications. Med Pediatr Oncol 1993; 21: 158-68. (Pubitemid 23084325)
18. Vujanic GM, Sandstedt B. The pathology of Wilms' tumour (nephroblastoma): the International Society of Paediatric Oncology approach. J Clin Pathol 2010; 63: 102-9.
19. Weirich A, Leuschner I, Harms D, et al. Clinical impact of histologic subtypes in localized non-anaplastic nephroblastoma treated according to the trial and study SIOP-9/GPOH. Ann Oncol 2001; 12: 311-9. (Pubitemid 32288685)
20. Bonadio JF, Storer B, Norkool P, Farewell VT, Beckwith JB, D'Angio GJ. Anaplastic Wilms' tumor: clinical and pathologic studies. J Clin Oncol 1985; 3: 513-20. (Pubitemid 15111399)
21. Zuppan CW, Beckwith JB, Weeks DA, Luckey DW, Pringle KC. The effect of preoperative therapy on the histologic features of Wilms' tumor. An analysis of cases from the Third National Wilms' Tumor Study. Cancer 1991; 68: 385-94.
22. Bove KE, McAdams AJ. The nephroblastomatosis complex and its relationship toWilms tumor: a clinicopathologic treatise. Perspect Pediatr Pathol 1976; 3: 185-223.
23. Beckwith JB. Nephrogenic rests and the pathogenesis of Wilms tumor: developmental and clinical considerations. Am J Med Genet 1998; 79: 268-73. (Pubitemid 28447107)
24. Baird PN, Santos A, Groves N, Jadresic L, Cowell JK. Constitutional mutations in the WT1 gene in patients with Denys-Drash syndrome. Hum Mol Genet 1992; 1: 301-5.
25. Pelletier J, Bruening W, Kashtan CE, et al. Germline mutations in the Wilms' tumor suppressor gene are associated with abnormal urogenital development in Denys-Drash syndrome. Cell 1991; 67: 437-47. (Pubitemid 121001458)
26. Weksberg R, Shuman C, Smith AC. Beckwith-Wiedemann syndrome. Am J Med Genet Part C Semin Med Genet 2005; 137C: 12-23. (Pubitemid 41113659)
27. Charles AK, Brown KW, Berry PJ. Microdissecting the genetic events in nephrogenic rests andWilms' tumor development. Am J Pathol 1998; 153: 991-1000. (Pubitemid 28419052)
28. Park S, Bernard A, Bove KE, et al. Inactivation of WT1 in nephrogenic rests, genetic precursors to Wilms tumour. Nat Genet 1993; 5: 363-7.
29. Knudson AG Jr, Strong LC. Mutation and cancer: a model for Wilms' tumor of the kidney. J Natl Cancer Inst 1972; 48: 313-24.
30. Breslow NE, Olson J, Moksness J, Beckwith JB, Grundy P. Familial Wilms' tumor: a descriptive study. Med Pediatr Oncol 1996; 27: 398-403. (Pubitemid 26327569)
31. Grundy P, Koufos A, Morgan K, Li FP, Meadows AT, Cavenee WK. Familial predisposition toWilms' tumour does not map to the short arm of chromosome 11. Nature 1988; 336: 374-6.
32. Huff V, Compton DA, Chao LY, Strong LC, Geiser CF, Saunders GF. Lack of linkage of familialWilms' tumour to chromosomal band 11p13. Nature 1988; 336: 377-8.
33. Haber DA, Sohn RL, Buckler AJ, Pelletier J, Call KM, Housman DE. Alternative splicing and genomic structure of theWilms tumor gene WT1. Proc Natl Acad Sci USA 1991; 88: 9618-22. (Pubitemid 21915682)
34. Morrison AA, Viney RL, Ladomery MR. The post-transcriptional roles of WT1, a multifunctional zinc-finger protein. Biochim Biophys Acta 2008; 1785: 55-62. (Pubitemid 350192082)
35. Kreidberg JA, Sariola H, Loring JM, et al. WT-1 is required for early kidney development. Cell 1993; 74: 679-91. (Pubitemid 23259748)
36. Pritchard-Jones K, Fleming S, Davidson D, et al. The candidate Wilms' tumour gene is involved in genitourinary development. Nature 1990; 346: 194-7.
37. Rivera MN, Haber DA. Wilms' tumor: connecting tumorigenesis and organ development in the kidney. Nat Rev 2005; 5: 699-712. (Pubitemid 41486363)
38. Gessler M, Konig A, Arden K, et al. Infrequent mutation of the WT1 gene in 77 Wilms' tumors. Hum Mutat 1994; 3: 212-22. (Pubitemid 24122238)
39. Huff V. Wilms tumor genetics. Am J Med Genet 1998; 79: 260-7. (Pubitemid 28447106)
40. Varanasi R, Bardeesy N, Ghahremani M, et al. Fine structure analysis of the WT1 gene in sporadic Wilms tumors. Proc Natl Acad Sci USA 1994; 91: 3554-8. (Pubitemid 24139468)
41. Fraizer G, Leahy R, Priyadarshini S, Graham K, Delacerda J, Diaz M. Suppression of prostate tumor cell growth in vivo by WT1, the Wilms' tumor suppressor gene. Int J Oncol 2004; 24: 461-71.
42. Smith SI, Down M, Boyd AW, Li CL. Expression of the Wilms' tumor suppressor gene, WT1, reduces the tumorigenicity of the leukemic cell line M1 in C.B-17 scid/scid mice. Cancer Res 2000; 60: 808-14. (Pubitemid 30129506)
43. Little M, Wells C. A clinical overview of WT1 gene mutations. Hum Mutat 1997; 9: 209-25. (Pubitemid 27138814)
44. Francke U, Holmes LB, Atkins L, Riccardi VM. Aniridia-Wilms' tumor association: evidence for specific deletion of 11p13. Cytogenet Cell Genet 1979; 24: 185-92. (Pubitemid 10220851)
45. Riccardi VM, Sujansky E, Smith AC, Francke U. Chromosomal imbalance in the Aniridia-Wilms' tumor association: 11p interstitial deletion. Pediatrics 1978; 61: 604-10.
46. Ton CC, Hirvonen H, Miwa H, et al. Positional cloning and characterization of a paired box- and homeobox-containing gene from the aniridia region. Cell 1991; 67: 1059-74. (Pubitemid 121001520)
47. Bonetta L, Kuehn SE, Huang A, et al. Wilms tumor locus on 11p13 defined by multiple CpG island-associated transcripts. Science 1990; 250: 994-7. (Pubitemid 120031807)
48. Gessler M, Poustka A, Cavenee W, Neve RL, Orkin SH, Bruns GA. Homozygous deletion in Wilms tumours of a zinc-finger gene identified by chromosome jumping. Nature 1990; 343: 774-8.
49. Call KM, Glaser T, Ito CY, et al. Isolation and characterization of a zinc finger polypeptide gene at the human chromosome 11Wilms' tumor locus. Cell 1990; 60: 509-20.
50. Chao LY, Huff V, Strong LC, Saunders GF. Mutation in the PAX6 gene in twenty patients with aniridia. Hum Mutat 2000; 15: 332-9. (Pubitemid 30194723)
51. Denys P, Malvaux P, Van Den Berghe H, Tanghe W, Proesmans W. [Association of an anatomo-pathological syndrome of male pseudohermaphroditism, Wilms' tumor, parenchymatous nephropathy and XX/XY mosaicism]. Arch Fr Pediatr 1967; 24: 729-39.
52. Mueller RF. The Denys-Drash syndrome. J Med Genet 1994; 31: 471-7. (Pubitemid 24182941)
53. Borel F, Barilla KC, Hamilton TB, Iskandar M, Romaniuk PJ. Effects of Denys-Drash syndrome point mutations on the DNA binding activity of the Wilms' tumor suppressor protein WT1. Biochemistry 1996; 35: 12070-6. (Pubitemid 26313678)
54. Little M, Holmes G, BickmoreW, van HeyningenV, Hastie N,Wainwright B. DNA binding capacity of the WT1 protein is abolished by Denys-Drash syndrome WT1 point mutations. Hum Mol Genet 1995; 4: 351-8.
55. Little S, Hanks S, King-Underwood L, et al. AWT1 exon 1 mutation in a child diagnosed with Denys-Drash syndrome. Pediatr Nephrol 2005; 20: 81-5. (Pubitemid 40057859)
56. Little MH, Williamson KA, Mannens M, et al. Evidence that WT1 mutations in Denys-Drash syndrome patients may act in a dominantnegative fashion. Hum Mol Genet 1993; 2: 259-64. (Pubitemid 23129085)
57. Frasier SD, Bashore RA, Mosier HD. Gonadoblastoma associated with pure gonadal dysgenesis in monozygous twins. J Pediatr 1964; 64: 740-5.
58. Moorthy AV, Chesney RW, Lubinsky M. Chronic renal failure and XY gonadal dysgenesis: 'Frasier' syndrome-a commentary on reported cases. Am J Med Genet Suppl 1987; 3: 297-302.
59. DeBaun MR, Tucker MA. Risk of cancer during the first four years of life in children from The Beckwith-Wiedemann Syndrome Registry. J Pediatr 1998; 132: 398-400. (Pubitemid 28180238)
60. Porteus MH, Narkool P, Neuberg D, et al. Characteristics and outcome of children with Beckwith-Wiedemann syndrome and Wilms' tumor: a report from the National Wilms Tumor Study Group. J Clin Oncol 2000; 18: 2026-31. (Pubitemid 30324354)
61. Scott RH, Stiller CA,Walker L, Rahman N. Syndromes and constitutional chromosomal abnormalities associated with Wilms tumour. J Med Genet 2006; 43: 705-15. (Pubitemid 44483912)
62. McTaggart SJ, Algar E, Chow CW, Powell HR, Jones CL. Clinical spectrum of Denys-Drash and Frasier syndrome. Pediatr Nephrol 2001; 16: 335-9. (Pubitemid 32366667)
63. Uccini S, Perotti D, Colarossi C, et al. Molecular evidence of the independent origin of multiple Wilms tumors in a case of WAGR syndrome. Pediatr Blood Cancer 2008; 51: 344-8.
64. Zhang TF, Yu SQ, Guan LS, Wang ZY. Inhibition of breast cancer cell growth by the Wilms' tumor suppressor WT1 is associated with a destabilization of beta-catenin. Anticancer Res 2003; 23 (5A): 3575-84.
65. Chang H, Gao F, Guillou F, Taketo MM, Huff V, Behringer RR. Wt1 negatively regulates beta-catenin signaling during testis development. Development 2008; 135: 1875-85.
66. Kim MK, McGarry TJ, O Broin P, Flatow JM, Golden AA, Licht JD. An integrated genome screen identifies the Wnt signaling pathway as a major target of WT1. Proc Natl Acad Sci USA 2009; 106: 11154-9.
67. Li CM, Kim CE, Margolin AA, et al. CTNNB1 mutations and overexpression of Wnt/beta-catenin target genes in WT1-mutant Wilms' tumors. Am J Pathol 2004; 165: 1943-53. (Pubitemid 39578373)
68. Maiti S, Alam R, Amos CI, Huff V. Frequent association of beta-catenin and WT1 mutations in Wilms tumors. Cancer Res 2000; 60: 6288-92.
69. Kim MS, Yoon SK, Bollig F, et al. A novel Wilms tumor 1 (WT1) target gene negatively regulates theWNT signaling pathway. J Biol Chem 2010; 285: 14585-93.
70. Haruta M, Arai Y, SugawaraW, et al. Duplication of paternal IGF2 or loss of maternal IGF2 imprinting occurs in half of Wilms tumors with various structural WT1 abnormalities. Genes Chromosomes Cancer 2008; 47: 712-27. (Pubitemid 351847583)
71. Huang H, Fujii H, Sankila A, et al. Beta-catenin mutations are frequent in human hepatocellular carcinomas associated with hepatitis C virus infection. Am J Pathol 1999; 155: 1795-801.
72. Morin PJ, Sparks AB, Korinek V, et al. Activation of beta-catenin-Tcf signaling in colon cancer by mutations in beta-catenin or APC. Science 1997; 275: 1787-90. (Pubitemid 27136715)
73. Koesters R, Ridder R, Kopp-Schneider A, et al. Mutational activation of the beta-catenin proto-oncogene is a common event in the development of Wilms' tumors. Cancer Res 1999; 59: 3880-2. (Pubitemid 29393544)
74. Clevers H. Wnt/beta-catenin signaling in development and disease. Cell 2006; 127: 469-80.
75. Tycko B, Li CM, Buttyan R. The Wnt/beta-catenin pathway in Wilms tumors and prostate cancers. Curr Mol Med 2007; 7: 479-89. (Pubitemid 47244893)
76. He TC, Sparks AB, Rago C, et al. Identification of c-MYC as a target of the APC pathway. Science 1998; 281: 1509-12. (Pubitemid 28425575)
77. Shtutman M, Zhurinsky J, Simcha I, et al. The cyclin D1 gene is a target of the beta-catenin/LEF-1 pathway. Proc Natl Acad Sci USA 1999; 96: 5522-7.
78. Brembeck FH, Rosario M, Birchmeier W. Balancing cell adhesion and Wnt signaling, the key role of beta-catenin. Curr Opin Genet Dev 2006; 16: 51-9. (Pubitemid 43089612)
79. Choi YS, Shim YM, Kim SH, et al. Prognostic significance of E-cadherin and beta-catenin in resected stage I non-small cell lung cancer. Eur J Cardiothorac Surg 2003; 24: 441-9. (Pubitemid 37083539)
80. Czyzewska J, Guzinska-Ustymowicz K, Ustymowicz M, Pryczynicz A, Kemona A. The expression of E-cadherin-catenin complex in patients with advanced gastric cancer: role in formation of metastasis. Folia Histochem Cytobiol 2010; 48: 37-45.
81. Fukuzawa R, Heathcott RW, More HE, Reeve AE. Sequential WT1 and CTNNB1 mutations and alterations of beta-catenin localisation in intralobar nephrogenic rests and associated Wilms tumours: two case studies. J Clin Pathol 2007; 60: 1013-6. (Pubitemid 47441934)
82. Fukuzawa R, Anaka MR, Heathcott RW, et al. Wilms tumour histology is determined by distinct types of precursor lesions and not epigenetic changes. J Pathol 2008; 215: 377-87.
83. Koesters R, Niggli F, von Knebel Doeberitz M, Stallmach T. Nuclear accumulation of beta-catenin protein in Wilms' tumours. J Pathol 2003; 199: 68-76. (Pubitemid 36054731)
84. Zirn B, Samans B, Wittmann S, et al. Target genes of the WNT/betacatenin pathway inWilms tumors. Genes Chromosomes Cancer 2006; 45: 565-74. (Pubitemid 43727163)
85. Ehrlich D, Bruder E, Thome MA, et al. Nuclear accumulation of betacatenin protein indicates activation of wnt signaling in chemically induced rat nephroblastomas. Pediatr Dev Pathol 2010; 13: 1-8.
86. Major MB, Camp ND, Berndt JD, et al. Wilms tumor suppressor WTX negatively regulates WNT/beta-catenin signaling. Science 2007; 316: 1043-6. (Pubitemid 46799493)
87. Grohmann A, Tanneberger K, Alzner A, Schneikert J, Behrens J. AMER1 regulates the distribution of the tumor suppressor APC between microtubules and the plasma membrane. J Cell Sci 2007; 120: 3738-47. (Pubitemid 350187356)
88. Rivera MN, Kim WJ,Wells J, et al. The tumor suppressor WTX shuttles to the nucleus and modulates WT1 activity. Proc Natl Acad Sci USA 2009; 106: 8338-43.
89. Jenkins ZA, van Kogelenberg M, Morgan T, et al. Germline mutations in WTX cause a sclerosing skeletal dysplasia but do not predispose to tumorigenesis. Nat Genet 2009; 41: 95-100.
90. Owen C, Virappane P, Alikian M, et al. WTX is rarely mutated in acute myeloid leukemia. Haematologica 2008; 93: 947-8. (Pubitemid 351821739)
91. Yoo NJ, Kim S, Lee SH. Mutational analysis of WTX gene in Wnt/betacatenin pathway in gastric, colorectal, and hepatocellular carcinomas. Dig Dis Sci 2009; 54: 1011-4.
92. Perotti D, Gamba B, Sardella M, et al. Functional inactivation of the WTX gene is not a frequent event in Wilms' tumors. Oncogene 2008; 27: 4625-32.
93. Rivera MN, Kim WJ, Wells J, et al. An X chromosome gene, WTX, is commonly inactivated in Wilms tumor. Science 2007; 315: 642-5. (Pubitemid 46214707)
94. Ruteshouser EC, Robinson SM, Huff V. Wilms tumor genetics: mutations in WT1, WTX, and CTNNB1 account for only about one-third of tumors. Genes Chromosomes Cancer 2008; 47: 461-70. (Pubitemid 351657181)
95. Wegert J, Wittmann S, Leuschner I, Geissinger E, Graf N, Gessler M. WTX inactivation is a frequent, but late event in Wilms tumors without apparent clinical impact. Genes Chromosomes Cancer 2009; 48: 1102-11.
96. Fukuzawa R, Anaka MR, Weeks RJ, Morison IM, Reeve AE. Canonical WNT signalling determines lineage specificity in Wilms tumour. Oncogene 2009; 28: 1063-75.
97. Fukuzawa R, Holman SK, Chow CW, Savarirayan R, Reeve AE, Robertson SP. WTX mutations can occur both early and late in the pathogenesis of Wilms tumour. J Med Genet 2010; 47: 791-4.
98. Reeve AE, Sih SA, Raizis AM, Feinberg AP. Loss of allelic heterozygosity at a second locus on chromosome 11 in sporadic Wilms' tumor cells. Mol Cell Biol 1989; 9: 1799-803. (Pubitemid 19095223)
99. Koufos A, Grundy P, Morgan K, et al. Familial Wiedemann-Beckwith syndrome and a second Wilms tumor locus both map to 11p15.5. Am J Hum Genet 1989; 44: 711-9. (Pubitemid 19119983)
100. Ping AJ, Reeve AE, Law DJ, Young MR, Boehnke M, Feinberg AP. Genetic linkage of Beckwith-Wiedemann syndrome to 11p15. Am J Hum Genet 1989; 44: 720-3. (Pubitemid 19119984)
101. Grundy P, Telzerow P, Paterson MC, et al. Chromosome 11 uniparental isodisomy predisposing to embryonal neoplasms. Lancet 1991; 338: 1079-80.
102. Henry I, Bonaiti-Pellie C, Chehensse V, et al. Uniparental paternal disomy in a genetic cancer-predisposing syndrome. Nature 1991; 351: 665-7. (Pubitemid 21896666)
103. Waziri M, Patil SR, Hanson JW, Bartley JA. Abnormality of chromosome 11 in patients with features of Beckwith-Wiedemann syndrome. J Pediatr 1983; 102: 873-6.
104. Maher ER, Reik W. Beckwith-Wiedemann syndrome: imprinting in clusters revisited. J Clin Invest 2000; 105: 247-52. (Pubitemid 30094443)
105. Smith AC, Choufani S, Ferreira JC, Weksberg R. Growth regulation, imprinted genes, and chromosome 11p15.5. Pediatr Res 2007; 61: 43R- 7R. (Pubitemid 46653067)
106. Zemel S, Bartolomei MS, Tilghman SM. Physical linkage of two mammalian imprinted genes, H19 and insulin-like growth factor 2. Nat Genet 1992; 2: 61-5.
107. Ogawa O, Eccles MR, Szeto J, et al. Relaxation of insulin-like growth factor II gene imprinting implicated inWilms' tumour. Nature 1993; 362: 749-51. (Pubitemid 23125978)
108. Rainier S, Johnson LA, Dobry CJ, Ping AJ, Grundy PE, Feinberg AP. Relaxation of imprinted genes in human cancer. Nature 1993; 362: 747-9. (Pubitemid 23125977)
109. Ravenel JD, Broman KW, Perlman EJ, et al. Loss of imprinting of insulinlike growth factor-II (IGF2) gene in distinguishing specific biologic subtypes of Wilms tumor. J Natl Cancer Inst 2001; 93: 1698.
110. Moulton T, Crenshaw T, Hao Y, et al. Epigenetic lesions at the H19 locus in Wilms' tumour patients. Nat Genet 1994; 7: 440-7. (Pubitemid 24204424)
111. Steenman MJ, Rainier S, Dobry CJ, Grundy P, Horon IL, Feinberg AP. Loss of imprinting of IGF2 is linked to reduced expression and abnormal methylation of H19 in Wilms' tumour. Nat Genet 1994; 7: 433-9. (Pubitemid 24204423)
112. Cui H, Hedborg F, He L, et al. Inactivation of H19, an imprinted and putative tumor repressor gene, is a preneoplastic event during Wilms' tumorigenesis. Cancer Res 1997; 57: 4469-73. (Pubitemid 27441046)
113. Watanabe N, Nakadate H, Haruta M, et al. Association of 11q loss, trisomy 12, and possible 16q loss with loss of imprinting of insulin-like growth factor-II in Wilms tumor. Genes Chromosomes Cancer 2006; 45: 592-601. (Pubitemid 43727166)
114. Bjornsson HT, Brown LJ, Fallin MD, et al. Epigenetic specificity of loss of imprinting of the IGF2 gene inWilms tumors. J Natl Cancer Inst 2007; 99: 1270-3. (Pubitemid 47299905)
115. Vuononvirta R, Sebire NJ, Dallosso AR, et al. Perilobar nephrogenic rests are nonobligate molecular genetic precursor lesions of insulin-like growth factor-II-associated Wilms tumors. Clin Cancer Res 2008; 14: 7635-44.
116. Donehower LA, Harvey M, Slagle BL, et al. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature 1992; 356: 215-21.
117. Lozano G. The oncogenic roles of p53 mutants in mouse models. Curr Opin Genet Dev 2007; 17: 66-70. (Pubitemid 46109293)
118. Sredni ST, Camargo B, Lopes LF, Teixeira R, Simpson A. Immunohistochemical detection of p53 protein expression as a prognostic indicator in Wilms tumor. Med Pediatr Oncol 2001; 37: 455-8. (Pubitemid 33029640)
119. Lahoti C, Thorner P, Malkin D, Yeger H. Immunohistochemical detection of p53 in Wilms' tumors correlates with unfavorable outcome. Am J Pathol 1996; 148: 1577-89. (Pubitemid 26135898)
120. Cheah PL, Looi LM, Chan LL. Immunohistochemical expression of p53 proteins in Wilms' tumour: a possible association with the histological prognostic parameter of anaplasia. Histopathology (Oxford) 1996; 28: 49-54. (Pubitemid 26041522)
121. Bardeesy N, Falkoff D, Petruzzi MJ, et al. Anaplastic Wilms' tumor, a subtype displaying poor prognosis, harbours p53 gene mutations. Nat Genet 1994; 7: 91-7.
122. Malkin D, Sexsmith E, Yeger H, Williams BR, Coppes MJ. Mutations of the p53 tumor suppressor gene occur infrequently in Wilms' tumor. Cancer Res 1994; 54: 2077-9. (Pubitemid 24138673)
123. Natrajan R, Little SE, Sodha N, et al. Analysis by array CGH of genomic changes associated with the progression or relapse of Wilms' tumour. J Pathol 2007; 211: 52-9. (Pubitemid 46092029)
124. Kaneko Y, Egues MC, Rowley JD. Interstitial deletion of short arm of chromosome 11 limited toWilms' tumor cells in a patient without aniridia. Cancer Res 1981; 41: 4577-8. (Pubitemid 12201377)
125. Grundy PE, Breslow NE, Li S, et al. Loss of heterozygosity for chromosomes 1p and 16q is an adverse prognostic factor in favorable-histology Wilms tumor: a report from the National Wilms Tumor Study Group. J Clin Oncol 2005; 23: 7312-21. (Pubitemid 46205952)
126. Yuan E, Li CM, Yamashiro DJ, et al. Genomic profiling maps loss of heterozygosity and defines the timing and stage dependence of epigenetic and genetic events in Wilms' tumors. Mol Cancer Res 2005; 3: 493-502. (Pubitemid 41377639)
127. Gow KW, Murphy JJ. Cytogenetic and histologic findings in Wilms' tumor. J Pediatr Surg 2002; 37: 823-7.
128. Kullendorff CM, Soller M, Wiebe T, Mertens F. Cytogenetic findings and clinical course in a consecutive series of Wilms tumors. Cancer Genet Cytogenet 2003; 140: 82-7. (Pubitemid 36110647)
129. Slater RM, Mannens MM. Cytogenetics and molecular genetics ofWilms' tumor of childhood. Cancer Genet Cytogenet 1992; 61: 111-21.
130. Bown N, Cotterill SJ, Roberts P, et al. Cytogenetic abnormalities and clinical outcome inWilms tumor: a study by the UK Cancer Cytogenetics Group and the UK Children's Cancer Study Group. Med Pediatr Oncol 2002; 38: 11-21. (Pubitemid 34037708)
131. Peres EM, Savasan S, Cushing B, Abella S, Mohamed AN. Chromosome analyses of 16 cases of Wilms tumor: different pattern in unfavorable histology. Cancer Genet Cytogenet 2004; 148: 66-70. (Pubitemid 38018882)
132. Frohling S, Dohner H. Chromosomal abnormalities in cancer. N Engl J Med 2008; 359: 722-34.
133. Cooper WN, Luharia A, Evans GA, et al. Molecular subtypes and phenotypic expression of Beckwith-Wiedemann syndrome. Eur J Hum Genet 2005; 13: 1025-32. (Pubitemid 43073609)
134. Natrajan R, Williams RD, Hing SN, et al. Array CGH profiling of favourable histology Wilms tumours reveals novel gains and losses associated with relapse. J Pathol 2006; 210: 49-58. (Pubitemid 44288180)
135. Hing S, Lu YJ, Summersgill B, et al. Gain of 1q is associated with adverse outcome in favorable histology Wilms' tumors. Am J Pathol 2001; 158: 393-8. (Pubitemid 32158602)
136. Messahel B, Williams R, Ridolfi A, et al. Allele loss at 16q defines poorer prognosis Wilms tumour irrespective of treatment approach in the UKW1-3 clinical trials: a Children's Cancer and Leukaemia Group (CCLG) Study. Eur J Cancer 2009; 45: 819-26.
137. Wittmann S, Zirn B, Alkassar M, Ambros P, Graf N, Gessler M. Loss of 11q and 16q in Wilms tumors is associated with anaplasia, tumor recurrence, and poor prognosis. Genes Chromosomes Cancer 2007; 46: 163-70. (Pubitemid 44913381)
138. Klamt B, Schulze M, Thate C, et al. Allele loss in Wilms tumors of chromosome arms 11q, 16q, and 22q correlate with clinicopathological parameters. Genes Chromosomes Cancer 1998; 22: 287-94. (Pubitemid 28304519)
139. Radice P, Perotti D, De Benedetti V, et al. Allelotyping in Wilms tumors identifies a putative third tumor suppressor gene on chromosome 11. Genomics 1995; 27: 497-501.
140. Ruteshouser EC, Hendrickson BW, Colella S, Krahe R, Pinto L, Huff V. Genome-wide loss of heterozygosity analysis of WT1-wild-type and WT1- mutant Wilms tumors. Genes Chromosomes Cancer 2005; 43: 172-80. (Pubitemid 40570737)
141. Rassekh SR, Chan S, Harvard C, Dix D, Qiao Y, Rajcan-Separovic E. Screening for submicroscopic chromosomal rearrangements in Wilms tumor using whole-genome microarrays. Cancer Genetics Cytogenet 2008; 182: 84-94. (Pubitemid 351491325)
142. Stock C, Ambros IM, Lion T, et al. Genetic changes of two Wilms tumors with anaplasia and a review of the literature suggesting a marker profile for therapy resistance. Cancer Genetics Cytogenetics 2002; 135: 128-38. (Pubitemid 34786764)
143. Benetkiewicz M, de Stahl TD, Gordor A, et al. Identification of limited regions of genetic aberrations in patients affected with Wilms' tumor using a tiling-path chromosome 22 array. Int J Cancer 2006; 119: 571-8. (Pubitemid 43955710)
144. Bea S, Salaverria I, Armengol L, et al. Uniparental disomies, homozygous deletions, amplifications, and target genes in mantle cell lymphoma revealed by integrative high-resolution whole-genome profiling. Blood 2009; 113: 3059-69.
145. Kratz CP, Steinemann D, Niemeyer CM, et al. Uniparental disomy at chromosome 11p15.5 followed by HRAS mutations in embryonal rhabdomyosarcoma: lessons from Costello syndrome. Hum Mol Genet 2007; 16: 374-9. (Pubitemid 46323174)
146. Murthy SK, DiFrancesco LM, Ogilvie RT, Demetrick DJ. Loss of heterozygosity associated with uniparental disomy in breast carcinoma. Mod Pathol 2002; 15: 1241-50. (Pubitemid 35462990)
147. Tuna M, Knuutila S, Mills GB. Uniparental disomy in cancer. Trends Mol Med 2009; 15: 120-8.
148. Shuman C, Smith AC, Steele L, et al. Constitutional UPD for chromosome 11p15 in individuals with isolated hemihyperplasia is associated with high tumor risk and occurs following assisted reproductive technologies. Am J Med Genet A 2006; 140: 1497-503. (Pubitemid 43993107)
149. Cooper WN, Curley R, Macdonald F, Maher ER. Mitotic recombination and uniparental disomy in Beckwith-Wiedemann syndrome. Genomics 2007; 89: 613-7. (Pubitemid 46589945)
150. Ohshima J, Haruta M, Arai Y, et al. Two candidate tumor suppressor genes, MEOX2 and SOSTDC1, identified in a 7p21 homozygous deletion region in a Wilms tumor. Genes Chromosomes Cancer 2009; 48: 1037-50.